<\/b><\/p>\n
<\/b><\/p>\n
MONDAY, Dec. 2, 2019 (HealthDay News) — Current statin use is inversely associated with the risk for lethal prostate cancer, according to a study published online Nov. 21 in Clinical Cancer Research<\/i>.<\/p>\n
Emma H. Allott, Ph.D., from Queen’s University Belfast in the United Kingdom, and colleagues prospectively examined statin use and lethal prostate cancer risk in the Health Professionals Follow-up Study. Data were included for 44,126 men who were cancer-free in 1990 and were followed for prostate cancer incidence through 2014; statin use was recorded biennially.<\/p>\n
The researchers found that 6,305 prostate cancers were diagnosed during 24 years of follow-up and 13 percent were lethal (metastatic at diagnosis or metastatic\/fatal during follow-up). Current statin use was inversely linked to risk for lethal prostate cancer relative to never\/past use (hazard ratio, 0.76; 95 percent confidence interval, 0.60 to 0.96), but it was not linked to overall disease. There was a strong inverse association for PTEN-null cancers (hazard ratio, 0.40; 95 percent confidence interval, 0.19 to 0.87) but not for PTEN-intact cancers (hazard ratio, 1.18; 95 percent confidence interval, 0.95 to 1.48). In normal prostates of ever and never users of statins, inflammation and immune pathways were enriched in 10 and 103 patients, respectively.<\/p>\n
“If confirmed, our findings provide support for a potential causal effect of statins on lethal prostate cancer risk and could help to inform the selection of appropriate biomarkers for use in statin clinical trials,” the authors write.<\/p>\n
Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n